Kane Biotech Receives Patent for Aledex Biofilm Technology in New Zealand

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, is pleased to announce the issuance of Patent No. 564904 entitled "Antimicrobial Compositions and Uses Thereof" by the New Zealand IP office.

Aledex is a synergistic and broad-spectrum combination of Protamine Sulfate and Chlorhexidine used to prevent microbial growth and biofilm formation. This patent covers the method of preventing growth and proliferation of biofilm-embedded microorganisms on medical devices such as urinary and vascular access catheters.

"We are very pleased that our unique Aledex biofilm technology for medical device coatings has been patented in New Zealand. We now have 14 issued and 28 pending patents covering our biofilm technology platforms," stated Gord Froehlich, President and CEO of Kane Biotech.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.